Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab784
Secukinumab improves the burden of heel enthesitis as assessed by patient and physician reported outcomes in patients with active SpA refractory to standard treatment. In coming to this conclusion, the ACHILLES trial aimed to demonstrate the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients.
Other important conclusions found that secukinumab does not provide a statistically significant resolution of Achilles tendon enthesitis at week 24 compared with placebo. Also highlighted was a clear discrepancy between the clinical and imaging assessments of enthesitis, highlighting a continuing unmet need in diagnosis. ACHILLES, therefore, sheds light into the understanding of the clinical and imaging assessments of enthesitis.